These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1142823)

  • 1. The menstrual cycle after withdrawal of oral contraceptives with particular reference to return of ovulation.
    Jordan K
    Mater Med Pol; 1975; 7(2):126-32. PubMed ID: 1142823
    [No Abstract]   [Full Text] [Related]  

  • 2. [The "sequential" method with a new estrogen-progesterone combination in ovulation control].
    Bailo U; Finzi C
    Minerva Ginecol; 1968 Dec; 20(23):1885-7. PubMed ID: 5734793
    [No Abstract]   [Full Text] [Related]  

  • 3. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
    Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seqential oral contraception.
    Zumpft CW
    Rocky Mt Med J; 1971 Mar; 68(3):39-42. PubMed ID: 5548697
    [No Abstract]   [Full Text] [Related]  

  • 5. Once-a-month oral contraceptive: quinestrol and quingestanol.
    Lotvin BR; Berman E
    Obstet Gynecol; 1970 Jun; 35(6):933-6. PubMed ID: 5446728
    [No Abstract]   [Full Text] [Related]  

  • 6. [Nucleic acids of mucous membrane cells of the corpus uteri in women in the course of the menstrual cycle induced by means of oral contraceptives].
    Rózewicki S
    Ann Acad Med Stetin; 1973; 0(0):5-60. PubMed ID: 4794550
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect and tolerance of a low dose ovulation inhibitor (Orlest)].
    Koester H; Hertel H
    Munch Med Wochenschr; 1969 Oct; 111(41):2103-9. PubMed ID: 5395280
    [No Abstract]   [Full Text] [Related]  

  • 8. [Side effects and especially uterine bleeding in women taking oral contraceptives].
    Bygdeman M; Svensson G; Westerholm B
    Lakartidningen; 1972 Dec; 69():Suppl 4:42-6. PubMed ID: 4656848
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pregnancy and oral contraceptives (author's transl)].
    Husstedt W
    Med Klin; 1974 Jan; 69(3):91-3. PubMed ID: 4816684
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic effects of a combination of dl-norgestrel and ethinylestradiol in humans.
    Gerhards E; Lachnit U; Gaude R; Schillinger E
    Arzneimittelforschung; 1973 Jun; 23(6):779-84. PubMed ID: 4740760
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effects of a contraceptive agent on the function of the peripheral and central menstrual cycle].
    Spona J; Schneider W; Matt K
    Med Klin; 1973 Apr; 68(16):505-9. PubMed ID: 4707380
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effects of partial components of a contraceptive agent on the function of the menstrual cycle].
    Schneider W; Spona J; Matt K
    Med Klin; 1973 Apr; 68(16):510-5. PubMed ID: 4707381
    [No Abstract]   [Full Text] [Related]  

  • 13. [A serial method for ovulation inhibition using ethinyl estradiol].
    McBride WG
    Arzneimittelforschung; 1969 Aug; 19(8):1271-3. PubMed ID: 5820291
    [No Abstract]   [Full Text] [Related]  

  • 14. [Ovulation inhibition with low dosage gestagen components. Results of international clinical trial of Orlest].
    Figoureux J; Onghena G; Schlikker E; Wattiez M; Schlösser W; Vercautere E; William P
    Munch Med Wochenschr; 1967 Dec; 109(48):2555-8. PubMed ID: 5631905
    [No Abstract]   [Full Text] [Related]  

  • 15. [Amenorrhea, anovulation and oligomenorrhea due to use of oral contraceptives].
    James M; Rozenbaum H
    Concours Med; 1974 Mar; 96(10):1559-60, 1563-4, 1567-8. PubMed ID: 4619979
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects of a cycle-regulating 2-phase preparation on peripheral and central cycle function].
    Schneider WH; Spona J; Matt K
    Ther Umsch; 1973 Jul; 30(7):516-23. PubMed ID: 4720331
    [No Abstract]   [Full Text] [Related]  

  • 17. [Partial inhibition of the excretion of the luteinizing hormone (LH) in the female urine by anti-ovulatory compounds].
    Morató Manaro J; Maggiolo J; Michelotti M; De Spremolla IM
    Med Klin; 1967 Nov; 62(47):1840-2. PubMed ID: 5591968
    [No Abstract]   [Full Text] [Related]  

  • 18. [A modified ovulation inhibitor of the sequence type: Tri-Ervonum].
    Tenhaeff D
    Fortschr Med; 1971 Sep; 89(26):1015-8. PubMed ID: 5154198
    [No Abstract]   [Full Text] [Related]  

  • 19. A double-blind comparison of two oral contraceptives containing 50 mu g. and 30 mu g. ethinyl estradiol.
    Dionne P; Vickerson F
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):281-8. PubMed ID: 4208342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Norgestrel and ethynyl estradiol: a new low-dosage oral agent for fertility control.
    Rice-Wray E; Avila C; Gutiérrez J
    Obstet Gynecol; 1968 Mar; 31(3):368-74. PubMed ID: 5639191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.